Cargando…

Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator

Ivacaftor (VX-770) was the first cystic fibrosis transmembrane conductance regulator (CFTR) modulatory drug approved for the treatment of patients with cystic fibrosis. Electron cryomicroscopy (cryo-EM) studies of detergent-solubilized CFTR indicated that VX-770 bound to a site at the interface betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laselva, Onofrio, Qureshi, Zafar, Zeng, Zhi-Wei, Petrotchenko, Evgeniy V., Ramjeesingh, Mohabir, Hamilton, C. Michael, Huan, Ling-Jun, Borchers, Christoph H., Pomès, Régis, Young, Robert, Bear, Christine E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184517/ https://www.ncbi.nlm.nih.gov/pubmed/34142049 http://dx.doi.org/10.1016/j.isci.2021.102542

Ejemplares similares

A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein
por: Laselva, Onofrio, et al.
Publicado: (2022)

Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
por: Chin, Stephanie, et al.
Publicado: (2019)

The cystic fibrosis transmembrane conductance regulator is an extracellular chloride sensor
por: Broadbent, Steven D., et al.
Publicado: (2014)

Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
por: Laselva, Onofrio, et al.
Publicado: (2022)

Molecular dynamics study of Cl(−) permeation through cystic fibrosis transmembrane conductance regulator (CFTR)
por: Zeng, Zhi Wei, et al.
Publicado: (2023)

666 Ivacaftor boosts cystic fibrosis transmembrane conductance regulator–mediated nasal potential difference in cystic fibrosis transmembrane conductance regulator knockout mice treated with human cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid lipid nanoparticle
por: Mukherjee, A., et al.
Publicado: (2022)

Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
por: Stanke, Frauke, et al.
Publicado: (2023)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis
por: Sergeev, Valentine, et al.
Publicado: (2020)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Synthesis and Properties of Molecular Probes for the Rescue Site on Mutant Cystic Fibrosis Transmembrane Conductance Regulator
por: Alkhouri, Bashar, et al.
Publicado: (2011)

Glycosylation and the cystic fibrosis transmembrane conductance regulator
por: Scanlin, Thomas F, et al.
Publicado: (2001)

Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data
por: McGarry, Lisa J., et al.
Publicado: (2023)

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
por: Schmidt, Béla Z, et al.
Publicado: (2016)

Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
por: Laselva, Onofrio, et al.
Publicado: (2019)

Acquired cystic fibrosis transmembrane conductance regulator dysfunction
por: Banks, Catherine, et al.
Publicado: (2018)

Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator
por: Villamizar, Olga, et al.
Publicado: (2019)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Cystic fibrosis transmembrane conductance regulator mutations at a referral center for cystic fibrosis
por: Coutinho, Cyntia Arivabeni de Araújo Correia, et al.
Publicado: (2013)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Expression of Cystic Fibrosis Transmembrane Conductance Regulator in Ganglia of Human Gastrointestinal Tract
por: Xue, Ruiqi, et al.
Publicado: (2016)

Alignment of transmembrane regions in the cystic fibrosis transmembrane conductance regulator chloride channel pore
por: Wang, Wuyang, et al.
Publicado: (2011)

The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
por: Meng, Xin, et al.
Publicado: (2016)

A transistor model for the cystic fibrosis transmembrane conductance regulator
por: Hunt, William D., et al.
Publicado: (2023)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
por: Christian, Francis, et al.
Publicado: (2019)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Cystic Fibrosis Transmembrane Conductance Regulator Folding Mutations Reveal Differences in Corrector Efficacy Linked to Increases in Immature Cystic Fibrosis Transmembrane Conductance Regulator Expression
por: Peters, Kathryn W., et al.
Publicado: (2021)

Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity
por: Malik, Firhan A., et al.
Publicado: (2015)

Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia
Publicado: (1992)

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis
por: Fukuda, Ryosuke, et al.
Publicado: (2020)

A Developmental Role of the Cystic Fibrosis Transmembrane Conductance Regulator in Cystic Fibrosis Lung Disease Pathogenesis
por: Huang, Elena N., et al.
Publicado: (2021)

Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
por: Harwood, Kiera H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4cauroabrjcs7gpdi3g9smfkc3